Figure 1
EAE-induced neurological motor deficits are similar between 3–4-month-old female and male C57BL/6 mice. Administration of the EAE-inducing agent myelin oligodendrocyte glycoprotein 35–55 (MOG35-55) was associated with neurological motor deficits as assessed with a clinical scoring system in female (A) and male (B) mice. Weak effects were also observed on grip strength (C and D, but see Figure 3B for significant effects at later time points). No differences in body weight were observed between the animals that received MOG35-55 versus CFA in either female (E) or male (F) mice. MOG35-55 injections began on day 0. BL baseline. Values represent mean ± SEM. ★P < 0.05 compared to sex- and age-matched CFA control (one-way ANOVA). N = 10–13/group.